Ocugen Inc (OCGN) Stock Price, Quote & News

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 328 4701

Website: www.ocugen.com

Address:

11 Great Valley Parkway, Malvern, United States

dgiudice Aug. 5 at 3:44 AM

$OCGN I guess I haven't been in the stock long enough. Now I know who CanSinoBio is! Very interesting.

0 · Reply

hotsoss Aug. 5 at 1:37 AM

$OCGN garbage

0 · Reply

Putnik Aug. 5 at 12:10 AM

$GLMD waiting for news here reminds me when I was in $OCGN at 1.30 back in 2021 waiting for news. Then it went to $17 on news. It was such nice gains that made me regret not getting more lol

1 · Reply

Djtrush Aug. 4 at 11:18 PM

$OCGN Is it ocugen you looking for?

3 · Reply

Reacherman Aug. 4 at 11:16 PM

$OCGN This is for all the new investors. The shorts have 11 days to cover and you will in this time here some very outlandish things that will remind you of a child throwing a tantrum. The bad thing is that stocktwits will let them go unchecked. There will be no spankings given LOL.

1 · Reply

Dynorod1 Aug. 4 at 11:01 PM

$OCGN

1 · Reply

Reacherman Aug. 4 at 10:52 PM

$OCGN 100%

0 · Reply

SGimvesting Aug. 4 at 10:44 PM

$OCGN

0 · Reply

Bulltrader988 Aug. 4 at 9:53 PM

$OCGN 👃👀 https://www.tipranks.com/news/blurbs/ocugen-ocgn-gets-a-buy-from-noble-financial-blurbs-2?utm_source=webullapp.com&utm_medium=referral

0 · Reply

CaptScotty Aug. 4 at 9:51 PM

$OCGN S. B. A. F. ! ™️

1 · Reply

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 8:25 AM EDT - 3 days ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Jul 21, 2025, 7:30 AM EDT - 14 days ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 18, 2025, 7:02 AM EDT - 17 days ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 17, 2025, 6:30 AM EDT - 18 days ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jun 23, 2025, 7:30 AM EDT - 6 weeks ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 18, 2025, 4:00 PM EDT - 6 weeks ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 16, 2025, 7:02 AM EDT - 7 weeks ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 11, 2025, 7:30 AM EDT - 7 weeks ago

Ocugen To Present at BIO International Convention 2025

Jun 5, 2025, 7:02 AM EDT - 2 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

May 27, 2025, 7:02 AM EDT - 2 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 9, 2025, 10:02 AM EDT - 3 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 8:01 AM EDT - 3 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 3 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 3 months ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 8, 2025, 8:02 AM EDT - 4 months ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Mar 18, 2025, 8:02 AM EDT - 4 months ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025, 10:59 AM EST - 5 months ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 7:02 AM EST - 5 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:46 AM EST - 5 months ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 21, 2025, 8:00 AM EST - 5 months ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:42 AM EST - 6 months ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 3, 2025, 6:30 AM EST - 6 months ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Jan 27, 2025, 6:30 AM EST - 6 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 16, 2025, 7:30 AM EST - 7 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 13, 2025, 6:30 AM EST - 7 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Dec 19, 2024, 6:38 AM EST - 8 months ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 11, 2024, 7:02 AM EST - 8 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 27, 2024, 7:09 AM EST - 8 months ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 7:30 AM EST - 9 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 19, 2024, 7:02 AM EST - 9 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 8, 2024, 10:18 AM EST - 9 months ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:45 AM EST - 9 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 7, 2024, 6:30 AM EST - 9 months ago

Ocugen Secures $30 Million in Debt Funding

Oct 28, 2024, 6:30 AM EDT - 10 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 22, 2024, 7:02 AM EDT - 10 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 17, 2024, 7:30 AM EDT - 10 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 9, 2024, 6:30 AM EDT - 10 months ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Oct 2, 2024, 6:30 AM EDT - 10 months ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Sep 24, 2024, 7:30 AM EDT - 11 months ago

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 8:00 AM EDT - 11 months ago

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Sep 17, 2024, 2:25 AM EDT - 11 months ago

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Sep 9, 2024, 6:30 AM EDT - 11 months ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Sep 5, 2024, 7:00 AM EDT - 11 months ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Sep 3, 2024, 7:30 AM EDT - 11 months ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Aug 26, 2024, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Aug 8, 2024, 6:45 AM EDT - 1 year ago

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Aug 5, 2024, 6:30 AM EDT - 1 year ago

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

dgiudice Aug. 5 at 3:44 AM

$OCGN I guess I haven't been in the stock long enough. Now I know who CanSinoBio is! Very interesting.

0 · Reply

hotsoss Aug. 5 at 1:37 AM

$OCGN garbage

0 · Reply

Putnik Aug. 5 at 12:10 AM

$GLMD waiting for news here reminds me when I was in $OCGN at 1.30 back in 2021 waiting for news. Then it went to $17 on news. It was such nice gains that made me regret not getting more lol

1 · Reply

Djtrush Aug. 4 at 11:18 PM

$OCGN Is it ocugen you looking for?

3 · Reply

Reacherman Aug. 4 at 11:16 PM

1 · Reply

Dynorod1 Aug. 4 at 11:01 PM

$OCGN

1 · Reply

Reacherman Aug. 4 at 10:52 PM

$OCGN 100%

0 · Reply

SGimvesting Aug. 4 at 10:44 PM

$OCGN

0 · Reply

Bulltrader988 Aug. 4 at 9:53 PM

$OCGN 👃👀 https://www.tipranks.com/news/blurbs/ocugen-ocgn-gets-a-buy-from-noble-financial-blurbs-2?utm_source=webullapp.com&utm_medium=referral

0 · Reply

CaptScotty Aug. 4 at 9:51 PM

$OCGN S. B. A. F. ! ™️

1 · Reply

bkhlr Aug. 4 at 9:33 PM

$OCGN

0 · Reply

Reacherman Aug. 4 at 8:27 PM

$OCGN I'm seeing 101 and 1.00

0 · Reply

bluesky16 Aug. 4 at 8:21 PM

$OCGN folks when is the payday.

1 · Reply

Reacherman Aug. 4 at 8:12 PM

$OCGN I'm showing we closed at 101

0 · Reply

CaptSparow Aug. 4 at 8:03 PM

$OCGN Silly bears 😂 You spent all day trying your dumps, oops, didn't work. Meanwhile I got to hang at the beach and didn't have to listen to the noise. Bliss!

0 · Reply